COVID-2019 Pipeline

Licensor	Licensor	Licensor	Licensor	Licensor	Licensor	Licensor	Licensor	Licensor
Argatroban	Weill Medical College of Cornell University	Thrombin (Factor IIa; F2)	Small molecule	Antithrombotic	Therapy	Phase IV	Approved globally	Blood clots, thrombocytopenia and others
Azithromycin	Multiple	Ribosomal 50S subunit	Small molecule	Antibiotic	Therapy	Phase IV	Approved globally	Bacterial infections
Dexamethasone	Multiple	Glucocorticoid receptor	Small molecule	Immunosuppressant	Therapy	Phase IV	Approved globally	Inflammatory conditions
Diovan valsartan	Radboud University	Angiotensin II type 1 (AT1) receptor (AGTR1)	Small molecule	Vasodilator	Therapy	Phase IV	Approved globally	Hypertension
Dipyridamole	Guangzhou Medical University	Phosphodiesterase (PDE)	Small molecule	Antithrombotic	Therapy	Phase IV	Approved globally	Prevent blood clots
Ebastine	Mianyang Central Hospital	Histamine H1 receptor (HRH1)	Small molecule	Immunosuppressant	Therapy	Phase IV	Approved globally	Allergic rhinitis
Enoxaparin	Weill Medical College of Cornell University	Factor Xa; Thrombin (Factor IIa; F2)	Polysaccharide	Antithrombotic	Therapy	Phase IV	Approved globally	Angina, myocardial infarction (MI) and others
Fondaparinux	Weill Medical College of Cornell University	Factor Xa	Small molecule	Antithrombotic	Therapy	Phase IV	Approved globally	Deep vein thrombosis (DVT), pulmonary embolism (PE) and others
Heparin	Multiple	Anti-thrombin III (AT3; SERPINC1)	Polysaccharide	Antithrombotic	Therapy	Phase IV	Approved globally	Blood clots
Humira adalimumab	Shanghai Changzheng Hospital	Tumor necrosis factor (TNF) alpha	Antibody	Immunosuppressant	Therapy	Phase IV	Approved globally	Autoimmune disorders
Hydrocortisone	Multiple	Corticoid receptors	Small molecule	Immunosuppressant	Therapy	Phase IV	Approved globally	Inflammation
Kaletra lopinavir / ritonavir (Aluvia)	AbbVie	HIV protease	Small molecule	Antiviral	Therapy	Phase IV	Approved globally	HIV
Linagliptin	University of Miami	Dipeptidyl peptidase-4 (DPP-4; CD26)	Small molecule	Metabolic	Therapy	Phase IV	Approved globally	Type II diabetes
Methylprednisolone	Multiple	Glucocorticoid receptor	Small molecule	Immunosuppressant	Therapy	Phase IV	Approved globally	Inflammatory conditions
Octagam 10%	Octapharma	Not determined	Antibody	Immunomodulator	Therapy	Phase IV	Approved in globally	Immunodeficiencies
Revlimid lenalidomide	Hospital Universitario Getafe	Cereblon (CRBN)	Small molecule	Antiangiogenic; Immunomodulator	Therapy	Phase IV	Approved globally	Hematological cancers
Olumiant baricitinib	Eli Lilly	Janus kinase-1 (JAK-1); JAK-2	Small molecule	Immunosuppressant	Therapy	Phase III	Approved globally	Rheumatoid arthritis
Actemra tocilizumab (RoActemra)	Roche	Interleukin-6 (IL-6) receptor (CD126)	Antibody	Immunosuppressant	Therapy	Phase III	Approved globally	Rheumatoid arthritis
Alvesco ciclesonide	Covis	Corticoid receptors	Small molecule	Immunosuppressant	Therapy	Phase III	Approved globally	Asthma
BCG Vaccine	Multiple	N/A	Live attenuated bacteria	Vaccine	Vaccine	Phase III	Approved globally	Tuberculosis

Latest News

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).

LEARN MORE

Pfizer Acquires Amplyx Pharmaceuticals

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

LEARN MORE

Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials

Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).

LEARN MORE

Join Our Newsletter

navigation